Current Clinical Trials

Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: Janssen
Details (Identifier #): NCT02407236
Title: CNTO1275UCO3001, A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Department: Oncology
Diagnosis: Hematology- Multiple Myeloma
Principal Investigator:
Sub-Investigator(s):
Sponsor: BMS
Details (Identifier #): NCT02726581
Title: BMS CA209-602, A Phase 2/3 Trial Combining Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Principal Investigator: Deshmukh MD, Pramod
Sponsor: St. Jude Medical
Title: A Clinical Evaluation of the Diagnostic Utility of MRI scans in patients implanted with St. Jude Medical pacemakers, ICDs, or CRTs.
Department: Cardiology
Diagnosis: Cardiac - Acute Coronary Syndrome
Principal Investigator: Kaluski MD, Edo
Sub-Investigator(s):
Sponsor: Zoll
Details (Identifier #): NCT01446965
Title: Prevention of Sudden Death After Myocardial Infarction Using a LifeVest Wearable Cardioverter-defibrillator
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: BMS
Details (Identifier #): NCT02477826
Title: Protocol CA209227: An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Department: Cardiology
Diagnosis: Cardiac - Device
Principal Investigator: Deshmukh MD, Pramod
Sponsor: St. Jude Medical
Title: A Clinical Evaluation of the Durata® or Optisure™ High Voltage (HV) Leads and Ellipse® VR ICD Undergoing Magnetic Resonance Imaging, an Investigational Device Exemption (IDE) Study